[go: up one dir, main page]

MX2020006075A - Composiciones farmaceuticas de bendamustina. - Google Patents

Composiciones farmaceuticas de bendamustina.

Info

Publication number
MX2020006075A
MX2020006075A MX2020006075A MX2020006075A MX2020006075A MX 2020006075 A MX2020006075 A MX 2020006075A MX 2020006075 A MX2020006075 A MX 2020006075A MX 2020006075 A MX2020006075 A MX 2020006075A MX 2020006075 A MX2020006075 A MX 2020006075A
Authority
MX
Mexico
Prior art keywords
bendamustine
pharmaceutical compositions
bendamustine pharmaceutical
pharmaceutical formulations
dry
Prior art date
Application number
MX2020006075A
Other languages
English (en)
Inventor
Vasilios Voudouris
Original Assignee
Vasilios Voudouris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasilios Voudouris filed Critical Vasilios Voudouris
Publication of MX2020006075A publication Critical patent/MX2020006075A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Proporcionadas aquí son formulaciones farmacéuticas de bendamustina en polvo seco adecuadas para uso farmacéutico. También se proporcionan métodos para producir bendamustina en polvo seco. Las formulaciones farmacéuticas pueden utilizarse para cualquier enfermedad que es sensible al tratamiento con bendamustina, tal como enfermedades neoplásicas.
MX2020006075A 2013-08-27 2016-02-25 Composiciones farmaceuticas de bendamustina. MX2020006075A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361870609P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
MX2020006075A true MX2020006075A (es) 2020-08-24

Family

ID=52584085

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002502A MX376522B (es) 2013-08-27 2014-08-22 Composiciones farmacéuticas de bendamustina.
MX2020006075A MX2020006075A (es) 2013-08-27 2016-02-25 Composiciones farmaceuticas de bendamustina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016002502A MX376522B (es) 2013-08-27 2014-08-22 Composiciones farmacéuticas de bendamustina.

Country Status (11)

Country Link
US (7) US9849115B2 (es)
EP (1) EP3043648B1 (es)
JP (1) JP6571657B2 (es)
CN (2) CN105491886B (es)
AU (5) AU2014311570C1 (es)
CA (1) CA2922099C (es)
ES (1) ES2957541T3 (es)
IL (1) IL244133A0 (es)
MX (2) MX376522B (es)
WO (1) WO2015031198A2 (es)
ZA (1) ZA201601645B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
US9320730B2 (en) * 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion
JP6937016B2 (ja) * 2017-09-06 2021-09-22 東京理化器械株式会社 噴霧乾燥装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
DE69808670T2 (de) * 1997-12-31 2003-07-03 Choongwae Pharma Corp., Seoul/Soul Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN1887261A (zh) 2006-07-25 2007-01-03 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
CN1887269A (zh) * 2006-07-25 2007-01-03 济南帅华医药科技有限公司 一种含苯达莫司汀及其增效剂的抗癌缓释注射剂
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
MX2011002936A (es) * 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
UA107186C2 (xx) 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
EA020354B1 (ru) 2008-12-03 2014-10-30 Астеллас Дойчланд Гмбх Пероральные лекарственные формы бендамустина
KR101798951B1 (ko) * 2009-02-25 2017-11-20 소프트케모 파마 코포레이션 벤다무스틴 환형다당류 조성물
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
PT2528602T (pt) 2010-01-28 2017-01-12 Eagle Pharmaceuticals Inc Formulações de bendamustina
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US20140142153A1 (en) 2011-01-25 2014-05-22 Dr. Reddy's Laboratories, Inc. Bendamustine formulations
WO2013102920A1 (en) 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
US9872873B2 (en) 2012-02-06 2018-01-23 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN104203235B (zh) * 2012-02-14 2018-11-23 赛多斯有限责任公司 苯达莫司汀的制剂
FI2827862T3 (fi) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Bendamustiinin formulaatioita
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
US9320730B2 (en) 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion

Also Published As

Publication number Publication date
AU2022263496A1 (en) 2022-12-08
US11701344B2 (en) 2023-07-18
WO2015031198A3 (en) 2015-04-23
EP3043648B1 (en) 2023-09-20
CN109953954A (zh) 2019-07-02
CN105491886B (zh) 2019-01-29
ES2957541T3 (es) 2024-01-22
ZA201601645B (en) 2017-04-26
AU2014311570A1 (en) 2016-03-10
EP3043648A2 (en) 2016-07-20
US20150065549A1 (en) 2015-03-05
CN105491886A (zh) 2016-04-13
AU2020286280A1 (en) 2021-01-14
WO2015031198A2 (en) 2015-03-05
AU2014311570C1 (en) 2018-08-02
US20220079923A1 (en) 2022-03-17
MX2016002502A (es) 2017-02-28
EP3043648C0 (en) 2023-09-20
JP6571657B2 (ja) 2019-09-04
CA2922099A1 (en) 2015-03-05
US10786486B2 (en) 2020-09-29
EP3043648A4 (en) 2017-11-22
US20240299363A1 (en) 2024-09-12
AU2014311570B2 (en) 2018-04-19
US9849115B2 (en) 2017-12-26
IL244133A0 (en) 2016-04-21
MX376522B (es) 2025-03-07
US20180071263A1 (en) 2018-03-15
US9061011B1 (en) 2015-06-23
AU2020286183A1 (en) 2021-01-07
US20230310381A1 (en) 2023-10-05
AU2018206777A1 (en) 2018-08-09
US20210008036A1 (en) 2021-01-14
CA2922099C (en) 2022-11-29
JP2016531138A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX364486B (es) Derivados de piridazinona-amidas.
IN2015DN01156A (es)
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015502161A1 (en) Therapeutic compounds and compositions
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EP3116528A4 (en) Adjuvant therapy to standard of care (soc) diuretic treatment
PH12015502703A1 (en) Pharmaceutical compositions
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
IN2013MU03855A (es)
TH1401006421A (th) สารประกอบสำหรับการใช้ในการผลิตยาสำหรับการรักษาโรคผิวหนังที่ตอบสนองต่อสเตียรอยด์